Radioiodinated metaiodobenzylguanidine (131I-MIBG) targeted radiation therapy for refractory or relapsed neuroblastoma
Record ID 32013000585
English
Authors' recommendations:
Neuroblastoma is a type of cancer that primarily affects infants and children. It accounts for about 18% of pediatric cancers and 15% of pediatric cancer deaths. Children with the best prognosis, especially those with a chance for long-term, disease-free survival, are those with localized, resectable neuroblastoma as well as infants 12 months or younger who are suffering from advanced disease. The 5-year event-free survival rate is < 50% for high-risk neuroblastoma, including patients with locoregional or metastatic disease. Neuroblastoma most commonly presents as an abdominal mass; however, other signs are caused by the tumor pressing against other tissues or from metastasis to bone. Signs of neuroblastoma include a mass in the abdomen, neck, or chest; bone pain; abdominal pain; emesis; weight loss; anorexia; fatigue; bulging eyes; dark circles around the eyes; and weakness or paralysis. Neuroblastoma is diagnosed by biopsy, ultrasonography, x-ray imaging, computed tomography (CT) scan, magnetic resonance imaging (MRI), and/or metaiodobenzylguanidine (MIBG) scan. Typical treatments include chemotherapy, radiation therapy, and surgery, depending on the extent and location of tumors. Patients with high-risk disease are treated with dose-intensive chemotherapy regimens, myeloablative hemotherapy,
autologous stem cell transplantation, and/or radiation therapy; however, despite intensive therapy, relapse is common and the long-term survival of children with high-risk disease is only 30%. There is an urgent need for new treatments that are effective without increased systemic toxicity.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=15054
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents
- Iodobenzenes
- Iodine Radioisotopes
- Neuroblastoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.